These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 29848341)
1. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. Lian X; Lin YM; Kozono S; Herbert MK; Li X; Yuan X; Guo J; Guo Y; Tang M; Lin J; Huang Y; Wang B; Qiu C; Tsai CY; Xie J; Gao ZJ; Wu Y; Liu H; Zhou XZ; Lu KP; Chen Y J Hematol Oncol; 2018 May; 11(1):73. PubMed ID: 29848341 [TBL] [Abstract][Full Text] [Related]
2. Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways. Zhang Z; Yu W; Zheng M; Liao X; Wang J; Yang D; Lu W; Wang L; Zhang S; Liu H; Zhou XZ; Lu KP Mol Carcinog; 2019 Aug; 58(8):1450-1464. PubMed ID: 31026381 [TBL] [Abstract][Full Text] [Related]
3. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways. Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha. Gianni' M; Boldetti A; Guarnaccia V; Rambaldi A; Parrella E; Raska I; Rochette-Egly C; Del Sal G; Rustighi A; Terao M; Garattini E Cancer Res; 2009 Feb; 69(3):1016-26. PubMed ID: 19155306 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959 [TBL] [Abstract][Full Text] [Related]
6. Pin1-Targeted Therapy for Systemic Lupus Erythematosus. Wei S; Yoshida N; Finn G; Kozono S; Nechama M; Kyttaris VC; Zhen Zhou X; Tsokos GC; Ping Lu K Arthritis Rheumatol; 2016 Oct; 68(10):2503-13. PubMed ID: 27159270 [TBL] [Abstract][Full Text] [Related]
7. PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers. Zhang ZZ; Yu WX; Zheng M; Liao XH; Wang JC; Yang DY; Lu WX; Wang L; Zhang S; Liu HK; Zhou XZ; Lu KP Mol Cancer Ther; 2020 Mar; 19(3):906-919. PubMed ID: 31879364 [TBL] [Abstract][Full Text] [Related]
8. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Wei S; Kozono S; Kats L; Nechama M; Li W; Guarnerio J; Luo M; You MH; Yao Y; Kondo A; Hu H; Bozkurt G; Moerke NJ; Cao S; Reschke M; Chen CH; Rego EM; Lo-Coco F; Cantley LC; Lee TH; Wu H; Zhang Y; Pandolfi PP; Zhou XZ; Lu KP Nat Med; 2015 May; 21(5):457-66. PubMed ID: 25849135 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. Lepore A; Choy PM; Lee NCW; Carella MA; Favicchio R; Briones-Orta MA; Glaser SS; Alpini G; D'Santos C; Tooze RM; Lorger M; Syn WK; Papakyriakou A; Giamas G; Bubici C; Papa S Hepatology; 2021 Nov; 74(5):2561-2579. PubMed ID: 34048060 [TBL] [Abstract][Full Text] [Related]
10. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345 [TBL] [Abstract][Full Text] [Related]
11. The role of Pin1 in the development and treatment of cancer. Min SH; Zhou XZ; Lu KP Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155 [TBL] [Abstract][Full Text] [Related]
12. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140 [TBL] [Abstract][Full Text] [Related]
13. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Kozono S; Lin YM; Seo HS; Pinch B; Lian X; Qiu C; Herbert MK; Chen CH; Tan L; Gao ZJ; Massefski W; Doctor ZM; Jackson BP; Chen Y; Dhe-Paganon S; Lu KP; Zhou XZ Nat Commun; 2018 Aug; 9(1):3069. PubMed ID: 30093655 [TBL] [Abstract][Full Text] [Related]
14. An irreversible inhibitor of peptidyl-prolyl cis/trans isomerase Pin1 and evaluation of cytotoxicity. Ieda N; Itoh K; Inoue Y; Izumiya Y; Kawaguchi M; Miyata N; Nakagawa H Bioorg Med Chem Lett; 2019 Feb; 29(3):353-356. PubMed ID: 30585173 [TBL] [Abstract][Full Text] [Related]
15. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. Pulikkan JA; Dengler V; Peer Zada AA; Kawasaki A; Geletu M; Pasalic Z; Bohlander SK; Ryo A; Tenen DG; Behre G Leukemia; 2010 May; 24(5):914-23. PubMed ID: 20376080 [TBL] [Abstract][Full Text] [Related]
16. All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis. Liu Y; Yu F; Dai S; Meng T; Zhu Y; Qiu G; Wen L; Zhou X; Yuan H; Hu F Mol Pharm; 2021 Nov; 18(11):3966-3978. PubMed ID: 34579532 [TBL] [Abstract][Full Text] [Related]
17. Targeting the SUMO Pathway Primes All- Baik H; Boulanger M; Hosseini M; Kowalczyk J; Zaghdoudi S; Salem T; Sarry JE; Hicheri Y; Cartron G; Piechaczyk M; Bossis G Cancer Res; 2018 May; 78(10):2601-2613. PubMed ID: 29487199 [TBL] [Abstract][Full Text] [Related]
18. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Ryo A; Uemura H; Ishiguro H; Saitoh T; Yamaguchi A; Perrem K; Kubota Y; Lu KP; Aoki I Clin Cancer Res; 2005 Oct; 11(20):7523-31. PubMed ID: 16243827 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. Yan X; Zhu Z; Xu S; Yang LN; Liao XH; Zheng M; Yang D; Wang J; Chen D; Wang L; Liu X; Liu J; Chen RH; Zhou XZ; Lu KP; Liu H Sci Rep; 2017 Apr; 7():45915. PubMed ID: 28383568 [TBL] [Abstract][Full Text] [Related]
20. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. Leong KW; Cheng CW; Wong CM; Ng IO; Kwong YL; Tse E Oncotarget; 2017 Feb; 8(7):11343-11355. PubMed ID: 28076852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]